Barrett's Esophagus: Sorting Out the Controversy
|
|
- Brendan Cobb
- 5 years ago
- Views:
Transcription
1 Barrett's Esophagus: Sorting Out the Controversy Learning Objectives 1. Identify the challenges in screening for Barrett s esophagus 2. Demonstrate comprehension of the risk of progression of Barrett s esophagus and dysplasia to cancer 3. Recognize the indications for referral for endoscopic eradication therapy 4. Outline the current limitations with surveillance endoscopy and endoscopic eradication therapies Faculty V. Raman Muthusamy, MD, FACG, FASGE Professor of Medicine Director of Endoscopy Division of Digestive Diseases David Geffen School of Medicine at UCLA Los Angeles, California Slides are current as of the time of printing and may differ from the live presentation due to copyright issues. Please reference for the most up-to-date version of slide sets. West Annual Conference Anaheim, California April 27-30, 2016
2 Barrett s esophagus: History Mr. Norman Barrett Pioneering thoracic surgeon ( ) Originally believed a congenitally shortened esophagus was key in pathogenesis; later accepted the concept of sliding hiatal hernia Also initially supported a developmental etiology for columnar-lined esophagus Current Definition of Barrett s Esophagus Barrett s esophagus (BE) implies replacement of a portion of the squamous epithelium of distal esophagus by specialized intestinal epithelium (IM). Three Essential Steps for Endoscopic Diagnosis and Description Recognize the squamocolumnar junction Identify gastroesophageal junction Describe extent of columnar mucosa AGA Barrett s Workshop, 2003 Tytgat GN, et al. Gastroenterol Clin North Am 1997; 26:507 The major endoscopic landmark for the gastroesophageal junction: The top of the gastric mucosal folds Barrett s esophagus: Prevalence Prevalence of BE in adults: % 880, million U.S. adults have BE In GI-select populations: 6-20% of patients undergoing endoscopy for GERD Up to 25% of an asymptomatic VA population Cameron AJ. Gastroenterol Clin North Am 1997;26: Winters C, et al. Barrett s esophagus. Gastro 1987;92: Ronkainen J, et al. Gastroenterology 2005;129: Sampliner RE, et al. Gastroenterology 2005;129: Rex DK, et al. Gastroenterology 2003;125: Gerson LB, et al. Gastroenterology. 2002;123: Ward EM, et al. Am J Gastroenterol. 2006;101:12 17.
3 Evolution of Barrett s esophagus Injury Acid & bile reflux nitrous oxide Genetics Gender, race,? other factors (cox-2) Accumulate Genetic Changes Natural History of HGD Most studies suggest 6-10% progression to cancer per year Wani et al, Am Journal of Gastro, 2009 Meta-analysis suggested 6.6%/yr Shaheen et al, NEJM, 2009 RCT of RFA vs. Surveillance HGD progression rate of 19% in 1 year in surveillance arm Rigorous confirmation of HGD pre-enrollment Rigor f/u and biopsy protocol Natural History of LGD: Earlier Data Interval LGD to HGD/Cancer Sharma, et al. 1 year risk 2.7% 5 year risk 13.5% Weston, et al. 1 year risk 3.1% 5 year risk 15.5% Skacel, et al. 1 year risk 12.7% 5 year risk 63.5% Lim, et al 1 year risk 3.3% 5 year risk 16.5% Wani, et al. 1 year risk 1.7% (cancer) 5 year risk 8.5 % (cancer) More Recent Data Regarding LGD Progression Meta-analysis suggests 1.7%/yr risk of progression to cancer Recent study (N=210) suggests 0.44%/yr to cancer with HGD progression of 1.6%/yr Another study of 147 LGD pts (85% of whom were downstaged) suggests progression rate of 13.4%/yr to HGD/CA and 85% risk of progression at months. Shaheen, NEJM, % progression to HGD in 1 year in surveillance arm Wani et al, Am Journal of Gastro, 2009 Wani et al, Gastroenterology 2011;141(4): Curvers WL, AM J Gastro 2010;105(7): Shaheen et al, NEJM, 2009; 360 (22): Natural History: BE without dysplasia Sharma, et al. Shaheen, et al. NDBE Progression LGD HGD Cancer 1 year risk 4.0% 0.9% 0.5% 5 year risk 20.0% 4.5% 2.5% 1 year risk na na 0.5% ( %) 5 year risk na na 2.5% ( %) Labenz, et al. 1 year risk na na 1.3% 5 year risk na na 6.5% Hvid-Jensen 1 year risk 0.12% Wani et al 1 year risk 0.6% (Meta-analysis) Bhat et al 1 year risk 0.13% 5 year risk 0.65% Wani et al 1 year risk 3.6% 0.48% 0.27%
4 Are We Underestimating Risk? Hvid-Jensen study eliminated 131 cancers found in 1 st year of study ( incident disease ) Without exclusion, rate goes for 0.12% to 0.36% Also excluded all HGD in 1 st year Misclassification of BE 32.3% of those w/ BE were not confirmed (95% CI ) in a community study VA study found 18% of LSBE and 33% of SSBE couldn t be confirmed Ganz GIE, 80: Should We Screen? BE associated with increased risk for esophageal adenocarcinoma (EAC) Potentially this risk is up to 40x that of the general population Risk of cancer between %/yr (all levels of dysplasia combined) EAC has dismal 17% 5-yr survival BE, however, may have negligible effect on overall mortality Which GERD Patients to Screen? Men > 50 years Caucasian race GERD symptoms for > 5 years Nocturnal Reflux Hiatal Hernia Elevated BMI Tobacco use Intra-abdominal distribution of body fat Screen patients with multiple risk factors: Weak rec., low-moderate quality evidence Don t need to rescreen negative patients: <=2.4% yield on f/u endoscopy AGA Medical Positional Statement on Management of BE, Gastroenterology 2011; 140: ASGE Guideline on BE and Other Premalignant Conditions of the Esophagus: GIE 2012; 76:6, Upper Endoscopy for GERD: Best Practice Advice from CGC of the ACP: Ann Int Med 2012; 157: The Barrett s Iceberg Prevalence of Barrett s in Subjects Undergoing Colonoscopy Most Barrett s Undetected Endoscopy: 22.6/100,000 Autopsy: 376.0/100,000 GERD symptoms not present in 60% of Barrett s patients in population based study Only 23/589 pts diagnosed with EAC in Kaiser study had known BE >= 6 months Cameron, et al. Gastroenterology 1990; 99: 918 Ronkainen et al, Gastroenterology, 2005; 129 (6): Corley DA et al, Gastroenterology 2002;122(3): % % 2.6% Heartburn n= % 5.6% BE LSBE SSBE 0.4% 5.2% No Heartburn n=556 Rex, et al. Gastroenterology 2003; 125:1670
5 How Should We Screen? Standard Endoscopy Unsedated Endoscopy Capsule Endoscopy? Sponge Cell Acquisition Device? Something else? (Blood/Saliva) Cytosponge for BE Screening Office-based, < 10 min Can be done by PCPs Tests for trefoil factor 3 Study of 504 pts 99% swallowed sponge 3% diagnosed with BE 73% Se and 94% Sp for >=1 cm of BE 90% Se and 93.5% Sp for >=2 cm of BE Kadri et al, BMJ 2010; 341 How Often or Long Should We Screen? CORI National endoscopic database 1/1/ /31/ ,406 pts had an initial EGD negative for BE and at least 1 subsequent EGD during the study period 2.3% (N=561) had? BE on f/u EGD (3.1% M:1.2% F) 9.9% BE on f/u EGD when esophagitis on initial exam vs. only 1.8% when no initial esophagitis Rodriguez S et al, Am Jl Gastro, 2008, 103: Technique of Biopsy in Endoscopic Surveillance Technique: NDBE: 4 quadrant q 2 cm Q 1 yr x 2; then q 3-5 yr LGD: 4 quadrant q 1 cm Repeat: Q 6-12 months HGD: 4 quadrant q 1 cm Repeat q 3 months Abrams JA, Clin Gastroenterol Hepatol 2009;7(7): Curvers WL Eur J Gastroenterol Hepatol 2008; 20(7): Compliance: US Study of 2245 cases Adherence rate was 51.2% Lower compliance with longer BE (N=150; Netherlands) 0-5 cm: 79% 5-10 cm: 50% 0-15 cm: 30% Problems with Surveillance Expensive ($596,000/QALY saved) Detects, not prevents, cancer Leads to patient anxiety Samples only 3-5% of mucosa Poor compliance associated with reduced dysplasia detection No quality data showing mortality reduction from EAC Population study showed only 23/589 pts diagnosed with EAC had known BE >= 6 mo Inadomi J, et al. Ann Intern Med 2003; 138:178 Corley DA, Gastroenterology 2002;122(3):
6 More on Surveillance Corley et al Gastro 145(2), Aug BE patients; 351 with adenocarcinoma 70 pts with prior dx of BE (51 dead; 38 from CA) Surveillance hx contrasted with 101 living BE pts Surveillance within 3 yrs: Not associated with decreased risk from CA (OR 0.99 [ ] Fatal cases received surveillance 55.3% of time; controls: 60.4% El-Serag HB et al, Gut, ,536 veterans with BE; 424 developed cancer over 5 yr f/u Surveillance associated with reduced risk of cancer related death (HR 0.47; ) Surveillance associated with earlier diagnosis, longer survival, and lower cancer related mortality Increased Yield with Specialized Brush 39.8% increase in Barrett s esophagus detection in GERD patients 42.1% increase in dysplasia detection c/t biopsy in patients w/ dysplasia undergoing surveillance Anandasapathy, Dig Dis Sci, 2011 Johanson, Dig Dis Sci, 2011 Surveillance Post Endoscopic Treatment: Is a Brush Better than Biopsies? AIM: Evaluate adjunctive value of specialized brush biopsy to forceps biopsy for detection of residual/recurrent BE after Barrett s ablation. 2 centers Specialized brush and standard biopsies taken at same session Specialized brushings taken first, then 4 quadrant q 1 cm random biopsies Abstract #345, Iorio et al, DDW 2015 Surveillance Post -Treatment: Is a Brush Better than Biopsies? Mean BE Length = 3.88 cm 18.8% (39/208) w/ IM, dysplasia, or neoplasia on forceps biopsy alone Specialized brush detected 24 additional cases (incremental yield of 11.5%) increasing detection of endpoint from 18.8% to 30.3% This is a 61% augmentation of the yield for IM, dyplasia, or neoplasia NNT = 8.7 to find one additional recurrence Abstract #345, Iorio et al, DDW 2015 Probe Based Confocal Laser Endomicroscopy A unique endomicroscopy system Probe-based system, used during endoscopic procedures Compatible with existing endoscopes Real-time visualization of tissue at the cellular level Access the entire GI tract Different probe types for different indications and needs Providing real-time visualization of tissues
7 Endoscopic Eradication Techiques (EET) for BE Endoscopic Mucosal Resection Thermal Ablation Argon Plasma Coagulation Multipolar Electrocoagulation Laser Ablation Radiofrequency Ablation Photochemical Ablation Photodynamic Therapy (PDT) Cryotherapy Ablation CO2 based Liquid Nitrogen based Endoscopic Mucosal Resection Diagnosis Staging Treatment When to perform EMR Evidence of any focal abnormality (typically raised, can be depressed) Lesions < 20 mm that require en bloc resection STAGING EMR 135 patients (HGD 92, EAC 43) undergoing EET at 3 centers Biopsy (HGD/EAC) EMR (within 3 months) Change in diagnosis in up to 45% Larger lesions can be resected in a piecemeal fashion Wani S et al, Dig Dis Sci 2013 Efficacy and Durability of RFA: Systematic Review and Meta-Analysis (Orman, Clin Gastroenterol Hepatol, 2013) Authors assessed: 18 studies of 3802 pts reporting efficacy 6 studies of 540 pts reporting durability CE-IM in 78% of pts; CE-D in 91% After eradication, IM recurred in 13% Median follow-up 16.5 months Progression to cancer: 0.2% of pts during treatment 0.7% of pts following CE-EM Stricture was most common adverse event, occurring in 5%Conclusion: Treatment of BE with RFA results in CE-D and CE-IM in a high proportion of pts, with few recurrences of IM after treatment and a low rate of adverse events. 52
8 AGA Medical Position Statement Gastroenterology 2011;140: HGD: Endotherapy with RFA, PDT, or EMR is recommended rather than surveillance LGD: RFA should be a therapeutic option for treatment of patients with confirmed LGD NDBE: RFA with or without EMR should be a therapeutic option for select individuals with NDBE who are judged to be at increased risk for progression to HGD or cancer SAGES Guideline Guideline for surgical treatment of GERD Includes section on management of Barrett s esophagus with evidence grading HGIN and IMC can be managed with RFA +/- EMR for eradication of lesion and reduction in cancer (Level I evidence) Surgery remains option for HGIN and IMC NDBE (IM), IND, LGD may be effectively eradicated with RFA (Level I evidence) Anti-reflux surgery for GERD may be performed in patients with NDBE (IM), IND, LGD in conjunction with endoscopic eradication therapy (i.e., before, during, after RFA) Source: ACG Guidelines 2015 For T1a cancer, endoscopic therapy is the preferred approach Endoscopic therapy is the preferred approach for confirmed LGD and HGD Agreement by two pathologists For LGD, some debate if LGD needs to be present on two occasions Non-dysplastic Barrett s should not be routinely treated with endoscopic ablative therapies due to its low risk of progression to esophageal cancer. Ablation Effect on Natural History Natural History (53 studies) After Ablation (65 studies) NDBE LGD HGD 0.6% 1.7% 6.6% 0.16% 0.16% 1.7% NNT=45 NNT=13 NNT= 4 Polyp 0.58% 0.06% NNT= 38 Progression risk expressed as Per-patient-per-year (%) risk of developing EAC NNT calculated on 5-year basis (number needed to treat to avoid one cancer over 5 years) Esophageal adenocarcinoma in BE: a meta-analysis. Wani S, et al. Am J Gastro 2009 Prevention of colorectal cancer by colonoscopic polypectomy. Winawer SJ, et al. NEJM 1993
9 NDBE: Who is High Risk? Family history? Long-segment? (>=3 cm) Young age? (<=60) History of prior dysplasia? Patient with poorly controlled GERD? Elevated BMI? Men? Hernia size? Rationale 50 y.o. man diagnosed with Long Segment NDBE Currently would get endoscopy at 51, 55, 59, 63, 67, 71, and 75 Assuming 3 ablation sessions, 1 yr f/u, 5 yr f/u, and 10 year f/u, would save 1 endoscopy and benefit from reduction in risk of progression. The Future: 7 Key Questions How do we best screen/identify patients with Barrett s Esophagus? What are the clinical and biomarker risk factors that predict progression of non-dysplastic BE? How can surveillance technique/yield be maximized? What are the risk factors for prolonged/failed ablation and recurrence? What are the appropriate post-ablation surveillance intervals? When, if ever, can surveillance post-ablation be stopped? In Whom? Is there a role for chemoprophylaxis? Proposed Future Algorithm for BE Inexpensive, Non-Invasive (Saliva/Blood), Highly Sensitive Screening Test for General Population Barrett's Esophagus Suspected Perform Endoscopy Barrett's Esophagus Confirmed Risk Stratification with Biomarker and Clinical Risk Panel Very Low Risk of Progression No Further Evaluation Low-Intermediate Risk of Progression Chemoprophylaxis and Surveillance No Further Evaluation High Risk of Progression Endoscopic Eradication Therapy No Barrett's Suspected No Further Evaluation Barrett's excluded Muthusamy & Sharma, GI Endoscopy Clinics N. Am, 2010 Conclusions A cost-effective screening method to identify patients with Barrett s esophagus is needed New strategies to increase the area sampled via surveillance should be developed. Confirmed Barrett s with dysplasia has a significant rate of progression and are amenable to endoscopic eradication therapies. Highly effective, safe, and durable endoscopic eradication techniques are available Clinical and biomarker risk factors that predict which non-dysplastic patients will progress to dysplasia and would benefit from treatment remain The Holy Grail of Barrett s Esophagus
Barrett s Esophagus. Abdul Sami Khan, M.D. Gastroenterologist Aurora Healthcare Burlington, Elkhorn, Lake Geneva, WI
Barrett s Esophagus Abdul Sami Khan, M.D. Gastroenterologist Aurora Healthcare Burlington, Elkhorn, Lake Geneva, WI A 58 year-old, obese white man has had heartburn for more than 20 years. He read a magazine
More informationManagement of Barrett s Esophagus. Case Presentation
Management of Barrett s Esophagus Lauren B. Gerson MD, MSc Associate Clinical Professor, UCSF Director of Clinical Research Gastroenterology Fellowship Program California Pacific Medical Center San Francisco,
More informationManagement of Barrett s: From Imaging to Resection
Management of Barrett s: From Imaging to Resection Michael Wallace, MD, MPH, FACG Professor of Medicine Mayo Clinic Florida Goals of Endoscopic Evaluation in Barrett s Detect Barrett s and dysplasia Reduce/eliminate
More informationMANAGEMENT OF BARRETT S RELATED NEOPLASIA IN 2018
MANAGEMENT OF BARRETT S RELATED NEOPLASIA IN 2018 Sachin Wani Medical Director Esophageal and Gastric Center Division of Gastroenterology and Hepatology University of Colorado Anschutz Medical Campus DISCLOSURES
More informationAGA SECTION. Gastroenterology 2016;150:
Gastroenterology 2016;150:1026 1030 April 2016 AGA Section 1027 Procedural intervention (3) Upper endoscopy indications 3 6 Non-response of symptoms to a 4 8 week empiric trial of twice-daily PPI Troublesome
More informationPresent Day Management of Barrett s Esophagus
Slide 1 Present Day Management of Barrett s Esophagus Kinnari R. Kher, M.D. Slide 2 Goals Risk factors for development of Barrett s esophagus Risks for progression to Esophageal Adenocarcinoma Current
More informationBarrett s Esophagus: Old Dog, New Tricks
Barrett s Esophagus: Old Dog, New Tricks Stuart Jon Spechler, M.D. Chief, Division of Gastroenterology, VA North Texas Healthcare System; Co-Director, Esophageal Diseases Center, Professor of Medicine,
More informationBarrett s Esophagus: What to Do for No Dysplasia, LGD, and HGD?
Barrett s Esophagus: What to Do for No Dysplasia, LGD, and HGD? Nicholas Shaheen, MD, MPH Center for Esophageal Diseases and Swallowing University of North Carolina 1 Outline What are the risks of progression
More informationAblation for Barrett s Esophagus: Burn or Freeze
Ablation for Barrett s Esophagus: Burn or Freeze John R. Saltzman MD Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School Disclosures No relevant disclosures
More informationRFA and Cyrotherapy for Esophageal Disease
RFA and Cyrotherapy for Esophageal Disease Daniel L. Miller MD Chief, General Thoracic Surgery WellStar Healthcare System/ Mayo Clinic Care Network Clinical Professor of Surgery Medical College of Georgia/
More informationBarrett s Esophagus: Ablate Everyone?
Nicholas J. Shaheen, MD, MPH, FACG Barrett s Esophagus: Ablate Everyone? Nicholas J. Shaheen, MD, MPH, FACG Center for Esophageal Diseases and Swallowing University of North Carolina Greetings from UNC,
More informationBarrett s esophagus. Barrett s neoplasia treatment trends
Options for endoscopic treatment of Barrett s esophagus Patrick S. Yachimski, MD MPH Director of Pancreatobiliary Endoscopy Assistant Professor of Medicine Division of Gastroenterology, Hepatology & Nutrition
More informationDefinition of GERD American College of Gastroenterology
Definition of GERD American College of Gastroenterology GERD is defined as chronic symptoms or mucosal damage produced by the abnormal reflux of gastric contents into the esophagus DeVault et al. Am J
More informationEndoscopic Management of Barrett s Esophagus
Endoscopic Management of Barrett s Esophagus Sammy Ho, MD Director of Pancreaticobiliary Services and Endoscopic Ultrasound Montefiore Medical Center Barrett s Esophagus Consequence of chronic GERD Mean
More informationEverything Esophagus: Barrett s Esophagus. Nicholas Shaheen, MD, MPH Center for Esophageal Diseases and Swallowing University of North Carolina
Everything Esophagus: Barrett s Esophagus Nicholas Shaheen, MD, MPH Center for Esophageal Diseases and Swallowing University of North Carolina The Most Important Thing Stayed the Same Adenocarcinoma A
More informationLearning Objectives:
Crescent City GI Update 2018 Ochsner Clinic, NOLA Optimizing Endoscopic Evaluation of Barrett s Esophagus What Should I Do in My Practice? Gregory G. Ginsberg, M.D. Professor of Medicine University of
More informationGregory G. Ginsberg, M.D.
Radiofrequency Ablation for Barrett s Esophagus with HGD Gregory G. Ginsberg, M.D. Professor of Medicine University of Pennsylvania School of Medicine Abramson Cancer Center Gastroenterology Division Executive
More informationJoel A. Ricci, MD SUNY Downstate Medical Center Department of Surgery
Joel A. Ricci, MD SUNY Downstate Medical Center Department of Surgery Norman Barrett (1950) described the esophagus as: that part of the foregut, distal to the cricopharyngeal sphincter, which is lined
More informationNew Developments in the Endoscopic Diagnosis and Management of Barrett s Esophagus
New Developments in the Endoscopic Diagnosis and Management of Barrett s Esophagus Prateek Sharma, MD Key Clinical Management Points: Endoscopic recognition of a columnar lined distal esophagus is crucial
More informationACG Clinical Guideline: Diagnosis and Management of Barrett s Esophagus
ACG Clinical Guideline: Diagnosis and Management of Barrett s Esophagus Nicholas J. Shaheen, MD, MPH, FACG 1, Gary W. Falk, MD, MS, FACG 2, Prasad G. Iyer, MD, MSc, FACG 3 and Lauren Gerson, MD, MSc, FACG
More informationDISCLOSURES. This program meets the requirements for GI specific Category 1 contact hours. M
DISCLOSURES Educational Dimensions is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center s Commission on Accreditation. Successful completion: Participants
More informationIs Radiofrequency Ablation Effective In Treating Barrett s Esophagus Patients with High-Grade Dysplasia?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 12-2016 Is Radiofrequency Ablation Effective
More informationCurrent Management: Role of Radiofrequency Ablation
Esophageal Adenocarcinoma And Barrett s Esophagus: Current Management: Role of Radiofrequency Ablation Ketan Kulkarni, MD Regional Gastroenterology Associates of Lancaster INTRODUCTION The prognosis of
More informationWhat s New in the Management of Esophageal Disease
What s New in the Management of Esophageal Disease Philip O. Katz, MD Chairman, Division of Gastroenterology Einstein Medical Center Philadelphia Clinical Professor of Medicine Jefferson Medical College
More informationScreening of Barrett: Is it cost-effective? Is there a high-risk population? T Ponchon Ed. Herriot Hospital Lyon, France
Screening of Barrett: Is it cost-effective? Is there a high-risk population? T Ponchon Ed. Herriot Hospital Lyon, France Barrett s esophagus (BE) is an acquired condition in which the normal squamous epithelium
More informationEndoscopic Radiofrequency Ablation or Cryoablation for Barrett Esophagus
Endoscopic Radiofrequency Ablation or Cryoablation for Barrett Esophagus Policy Number: Original Effective Date: MM.02.005 09/01/2010 Line(s) of Business: Current Effective Date: PPO; HMO; QUEST Integration
More informationEndoscopic Radiofrequency Ablation or Cryoablation for Barrett s Esophagus
Endoscopic Radiofrequency Ablation or Cryoablation for Barrett s Esophagus Policy Number: 2.01.80 Last Review: 6/2018 Origination: 6/2012 Next Review: 6/2019 Policy Blue Cross and Blue Shield of Kansas
More informationBarrett s Esophagus: State of the Art. Food Getting Stuck
Barrett s Esophagus: State of the Art Nicholas J. Shaheen, MD, MPH Center for Esophageal Diseases and Swallowing University of North Carolina SOM Food Getting Stuck 73-year-old retired Wilmington police
More informationHistory. Prevalence at Endoscopy. Prevalence and Reflux Sx. Prevalence at Endoscopy. Barrett s Esophagus: Controversy and Management
Barrett s Esophagus: Controversy and Management History Norman Barrett (1950) Chronic Peptic Ulcer of the Oesophagus and Oesophagitis Allison and Johnstone (1953) The Oesophagus Lined with Gastric Mucous
More informationMedicare Advantage Medical Policy
Medicare Advantage Medical Policy Current Policy Effective Date: 1/1/18 Title: Endoscopic Radiofrequency Ablation or Cryoablation for Barrett Esophagus Description/Background Barrett Esophagus and the
More informationSlide 1. Slide 2. Slide 3 DISCLOSURES EXPECTED OUTCOMES DIAGNOSIS AND TREATMENT
Slide 1 DIAGNOSIS AND TREATMENT 1 Slide 2 DISCLOSURES Successful completion: Participants must attend the entire program, including any resulting Q & A, and submit required documentation. Conflict of interest:
More informationChanges to the diagnosis and management of Barrett s Oesophagus
Changes to the diagnosis and management of Barrett s Oesophagus A review of the new BSG and NICE guidelines and best practice Anjan Dhar DM, MD, FRCPE, AGAF, MBBS (Hons.), Cert. Med. Ed Senior Lecturer
More informationBarrett s Esophagus. lining of the lower esophagus that bears his name (i.e., Barrett's esophagus). We now
Shamika Johnson Anatomy & Physiology 206 April 20, 2010 Barrett s Esophagus What is Barrett s Esophagus? Norman Barrett was a pathologist. In 1950, he described an abnormality in the lining of the lower
More informationDisclosures. Gastroesophageal Reflux Disease. Gastroesophageal Reflux Disease
Kunal Jajoo, MD Brigham and Women s Hospital July 2012 Disclosures Spouse is a physician employed by Boston Scientific Corporation The content of this lecture equitably discusses products of multiple companies
More informationFaculty Disclosure. Objectives. State of the Art #3: Referrals for Gastroscopy (focus on common esophagus problems) 24/11/2014
State of the Art #3: Referrals for Gastroscopy (focus on common esophagus problems) Dr. Amy Morse November 2014 Faculty: Amy Morse Faculty Disclosure Relationships with commercial interests: Grants/Research
More informationThis medical position statement considers a series of
GASTROENTEROLOGY 2011;140:1084 1091 American Gastroenterological Association Medical Position Statement on the Management of Barrett s Esophagus The Institute Medical Position Panel consisted of the authors
More informationPage 1. Is the Risk This High? Dysplasia in the IBD Patient. Dysplasia in the Non IBD Patient. Increased Risk of CRC in Ulcerative Colitis
Screening for Colorectal Neoplasia in Inflammatory Bowel Disease Francis A. Farraye MD, MSc Clinical Director, Section of Gastroenterology Co-Director, Center for Digestive Disorders Boston Medical Center
More informationHow to remove BE cancer: EMR or ESD? Expected outcome
How to remove BE cancer: EMR or ESD? Expected outcome Presented by Horst Neuhaus Institution Dpt. of Gastroenterology Evangelisches Krankenhaus Düsseldorf, Germany Indications for endoscopic resection
More informationBarrett s Esophagus. Radiofrequency Ablation with the HALO Technology A Reference Book
Radiofrequency Ablation with the HALO Technology A Reference Book 540 Oakmead Parkway, Sunnyvale, CA 94085 What is Barrett s esophagus? Barrett s esophagus is a change that occurs within the cellular lining
More informationBarrett s Esophagus: Review of Diagnostic Issues and Pre- Neoplastic Lesions
Barrett s Esophagus: Review of Diagnostic Issues and Pre- Neoplastic Lesions Robert Odze, MD, FRCPC Chief, Gastrointestinal Pathology Associate Professor of Pathology Brigham and Women s Hospital Harvard
More informationCitation for published version (APA): Phoa, K. Y. N. (2014). Endoscopic management of Barrett s esophagus with dysplasia
UvA-DARE (Digital Academic Repository) Endoscopic management of Barrett s esophagus with dysplasia Phoa, Nadine Link to publication Citation for published version (APA): Phoa, K. Y. N. (2014). Endoscopic
More informationChapter 2 Complications of Gastroesophageal Reflux Disease
Chapter 2 Complications of Gastroesophageal Reflux Disease Patrick Yachimski Acute esophageal exposure to gastric and/or duodenal refluxate can result in pyrosis and symptomatic gastroesophageal reflux
More informationAccepted Manuscript. CGH Editorial: Sound the Alarm for Barrett s Screening! Tarek Sawas, M.D., M.P.H., David A. Katzka, M.D
Accepted Manuscript CGH Editorial: Sound the Alarm for Barrett s Screening! Tarek Sawas, M.D., M.P.H., David A. Katzka, M.D PII: S1542-3565(18)31093-0 DOI: 10.1016/j.cgh.2018.10.010 Reference: YJCGH 56132
More informationCryospray ablation using pressurized CO 2 for ablation of Barrett s esophagus with early neoplasia: early termination of a prospective series
E17 Cryospray ablation using pressurized CO 2 for ablation of Barrett s esophagus with early neoplasia: early termination of a prospective series Authors Romy E. Verbeek 1, Frank P. Vleggaar 1, Fiebo J.
More informationHiatal Hernias and Barrett s esophagus. Dr Sajida Ahad Mercy General Surgery
Hiatal Hernias and Barrett s esophagus Dr Sajida Ahad Mercy General Surgery Objectives Identify the use of different diagnostic modalities for hiatal hernias List the different types of hiatal hernias
More informationVolumetric laser endomicroscopy can target neoplasia not detected by conventional endoscopic measures in long segment Barrett s esophagus
E318 Volumetric laser endomicroscopy can target neoplasia not detected by conventional endoscopic measures in long segment esophagus Authors Institution Arvind J. Trindade, Benley J. George, Joshua Berkowitz,
More informationBarrett s Esophagus: State of the Art Management
In the Name of God Barrett s Esophagus: State of the Art Management Siavosh Nasseri-Moghaddam MD, MPH, AGAF Associate Professor of Medicine Digestive Disease Research Center, Shariati Hospital, TUMS IAGH
More informationEndoscopic Radiofrequency Ablation or Cryoablation for Barrett`s Esophagus. Original Policy Date
MP 2.01.52 Endoscopic Radiofrequency Ablation or Cryoablation for Barrett`s Esophagus Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature
More informationWhat Is Barrett s Esophagus?
What Is Barrett s Esophagus? Having Barrett s esophagus means the cells lining the esophagus (the tube that links the mouth and the stomach) have changed into types of intestinal cells that are not normal
More informationOpinion Statement. Esophagus (E Dellon, Section Editor)
Curr Treat Options Gastro (2016) 14:1 18 DOI 10.1007/s11938-016-0080-4 Esophagus (E Dellon, Section Editor) Current Controversies in Radiofrequency Ablation Therapy for Barrett s Esophagus Kamar Belghazi,
More informationRecurrent intestinal metaplasia at the gastroesophageal junction following endoscopic eradication of dysplastic Barrett s esophagus may not be benign
THIEME E849 Recurrent intestinal metaplasia at the gastroesophageal junction following endoscopic eradication of dysplastic Barrett s esophagus may not be benign Authors Georgina R. Cameron 1, 3, Paul
More informationAdherence to Surveillance Guidelines in Nondysplastic Barrett s Esophagus.
Adherence to Surveillance Guidelines in Nondysplastic Barrett s Esophagus. Kunal S. Dalal, MD 1 ; Jessica Coffing, MPH 2 ; Thomas F. Imperiale, MD 1 Affiliations: 1 Indiana University School of Medicine,
More informationSixteen-year follow-up of Barrett s esophagus, endoscopically treated with argon plasma coagulation
Original Article Sixteen-year of Barrett s esophagus, endoscopically treated with argon plasma coagulation United European Gastroenterology Journal 2014, Vol. 2(5) 367 373! Author(s) 2014 Reprints and
More informationAmerican Journal of Gastroenterology. Volumetric Laser Endomicroscopy Detects Subsquamous Barrett s Adenocarcinoma
Volumetric Laser Endomicroscopy Detects Subsquamous Barrett s Adenocarcinoma Journal: Manuscript ID: AJG-13-1412.R1 Manuscript Type: Letter to the Editor Keywords: Barrett-s esophagus, Esophagus, Endoscopy
More informationCurrent Management of Low-Grade Dysplasia in Barrett Esophagus
Current Management of Low-Grade Dysplasia in Barrett Esophagus Gary W. Falk, MD, MS Dr Falk is a professor of medicine in the Division of Gastroenterology at the University of Pennsylvania Perelman School
More informationFrom reflux to esophageal cancer. Josh Boys, MD TCV 2 nd year indentured servant
From reflux to esophageal cancer Josh Boys, MD TCV 2 nd year indentured servant The Pathway Esophageal Squamous epithelium+reflux Columnar lined esophagus (CLE) or Cardiac mucosa Intestinal Metaplasia
More informationPopulations Interventions Comparators Outcomes Individuals: With Barrett esophagus with high-grade dysplasia
Endoscopic Radiofrequency Ablation or Cryoablation for Barrett (20180) Medical Benefit Effective Date: 01/01/16 Next Review Date: 09/19 Preauthorization No Review Dates: 05/09, 03/10, 03/11, 03/12, 07/12,
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Ablation. See specific types, e.g., Thermal ablation Achalasia, 53 75 described, 53 features of, 53 management of past options, 54 POEM
More informationHistopathology of Endoscopic Resection Specimens from Barrett's Esophagus
Histopathology of Endoscopic Resection Specimens from Barrett's Esophagus Br J Surg 38 oct. 1950 Definition of Barrett's esophagus A change in the esophageal epithelium of any length that can be recognized
More informationSection: Medicine Effective Date: July 15, 2015 Subsection: Original Policy Date: December 7, 2011 Subject:
Last Review Status/Date: June 2015 Page: 1 of 16 Cryoablation for Barrett s Esophagus Description Barrett s esophagus (BE) is a condition in which the normal squamous epithelium is replaced by specialized
More informationFollow this and additional works at:
Washington University School of Medicine Digital Commons@Becker Open Access Publications 217 Recurrence of intestinal metaplasia and early neoplasia after endoscopic eradication therapy for Barrett s esophagus:
More informationBarrett esophagus. Bible class Inselspital
Barrett esophagus Bible class Inselspital 2015.08.10 Guidelines Definition? BSG: ACG: Definition? BSG: ACG: What are the arguments for and against IM as prerequisite for the Dg? What are the arguments
More informationACG Clinical Guideline: Diagnosis and Management of Barrett s Esophagus
30 PRACTICE GUIDELINES nature publishing group CME ACG Clinical Guideline: Diagnosis and Management of Barrett s Esophagus Nicholas J. Shaheen, MD, MPH, FACG 1, Gary W. Falk, MD, MS, FACG 2, Prasad G.
More informationEvaluating Treatments of Barrett s Esophagus That Shows High-Grade Dysplasia
...PRESENTATIONS... Evaluating Treatments of Barrett s Esophagus That Shows High-Grade Dysplasia Based on a presentation by Bergein F. Overholt, MD Presentation Summary Thermal ablation and surgery are
More informationHow to characterize dysplastic lesions in IBD?
How to characterize dysplastic lesions in IBD? Name: Institution: Helmut Neumann, MD, PhD, FASGE University Medical Center Mainz What do we know? Patients with IBD carry an increased risk of developing
More informationDysplas'c Barre- s Esophagus: Cut, Burn, Freeze or Watch Very Very Closely
Dysplas'c Barre- s Esophagus: Cut, Burn, Freeze or Watch Very Very Closely Felice Schnoll- Sussman, MD, FACG Director, Jay Monahan Center Associate Professor Clinical Medicine Weill Cornell Medical Center
More informationBarrett s Oesophagus Information Leaflet THE DIGESTIVE SYSTEM. gutscharity.org.
THE DIGESTIVE SYSTEM http://healthfavo.com/digestive-system-for-kids.html This factsheet is about Barrett s Oesophagus Barrett s Oesophagus is the term used for a pre-cancerous condition where the normal
More informationOriginal article INTRODUCTION
Diseases of the Esophagus (2014), DOI: 10.1111/dote.12166 Original article A Barrett s esophagus registry of over 1000 patients from a specialist center highlights greater risk of progression than population-based
More informationRelative risk of dysplasia for patients with intestinal metaplasia in the distal oesophagus and in the gastric cardia
Gut 2000;46:9 13 9 PAPERS Division of Gastroenterology, University of Kansas, VA Medical Center, Kansas City, Missouri, USA P Sharma A P Weston Department of Pathology, VA Medical Center, Kansas M Topalovski
More informationBarrett s esophagus (BE), a known complication of chronic
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2011;9:220 227 Patients With Nondysplastic Barrett s Esophagus Have Low Risks for Developing Dysplasia or Esophageal Adenocarcinoma SACHIN WANI,* GARY FALK, MATTHEW
More informationReview Article Outcomes of Radiofrequency Ablation for Dysplastic Barrett s Esophagus: A Comprehensive Review
Gastroenterology Research and Practice Volume 2016, Article ID 4249510, 8 pages http://dx.doi.org/10.1155/2016/4249510 Review Article Outcomes of Radiofrequency Ablation for Dysplastic Barrett s Esophagus:
More informationGI CANCER SCREENING- Is It Worth It? Sylvia M. Oats, MSN, APRN, ANP-BC Susan H. Miedecke, MSN, APRN, FNP-BC Gastroenterology Clinic of Acadiana
GI CANCER SCREENING- Is It Worth It? Sylvia M. Oats, MSN, APRN, ANP-BC Susan H. Miedecke, MSN, APRN, FNP-BC Gastroenterology Clinic of Acadiana Life is a sexually transmitted disease, and the mortality
More informationDisclosures. Heartburn and Barrett s Esophagus. Heartburn and Barrett s Esophagus. GERD is common in the U.S. None
Heartburn and Barrett s Esophagus None Disclosures Christian Mathy, MD University of California, San Francisco 2015 Heartburn and Barrett s Esophagus Heartburn and GERD GERD therapy Extraesophageal GERD
More informationSpeaker disclosure. Objectives. GERD: Who and When to Treat 7/21/2015
GERD: Who and When to Treat Eugenio J Hernandez, MD Gastrohealth, PL Assistant Professor of Clinical Medicine, FIU Herbert Wertheim School of Medicine Speaker disclosure I do not have any relevant commercial
More informationEndoscopic Submucosal Dissection ESD
Endoscopic Submucosal Dissection ESD Peter Draganov MD Professor of Medicine Division of Gastroenterology, Hepatology and Nutrition University of Florida Gastrointestinal Cancer Lesion that Can be Treated
More informationPancreatic Cystic Neoplasms: Guidelines and beyond
Pancreatic Cystic Neoplasms: Guidelines and beyond Kenneth J. Chang, MD, FACG, FASGE Executive Director, Comprehensive Digestive Disease Center Professor and Chief, Gastroenterology Vincent & Anna Kong
More informationEditorial: Advanced endoscopic therapeutics in Barrett s neoplasia; where are we now and where are we heading?
Editorial: Advanced endoscopic therapeutics in Barrett s neoplasia; where are we now and where are we heading? Dr. Gaius Longcroft-Wheaton MB,BS, MD, MRCP(UK), MRCP(Gastro) Consultant gastroenterologist
More informationCDx Diagnostics THE NEW STANDARD FOR QUALITY GI CARE
CDx Diagnostics THE NEW STANDARD FOR QUALITY GI CARE STUDYDESIGN 16 major academic GI centers participated in a double-blind, randomized, crossover study in which 160 high-risk patients undergoing BE surveillance
More informationPatterns of recurrent and persistent intestinal metaplasia after successful radiofrequency ablation of Barrett s esophagus
Patterns of recurrent and persistent intestinal metaplasia after successful radiofrequency ablation of Barrett s esophagus Robert J. Korst, MD, a,b Sobeida Santana-Joseph, MSN, a,b John R. Rutledge, MAS,
More informationAlberta Colorectal Cancer Screening Program (ACRCSP) Post Polypectomy Surveillance Guidelines
Alberta Colorectal Cancer Screening Program (ACRCSP) Post Polypectomy Surveillance Guidelines June 2013 ACRCSP Post Polypectomy Surveillance Guidelines - 2 TABLE OF CONTENTS Background... 3 Terms, Definitions
More informationTreatment of High-Grade Dysplasia and Early Stage Esophageal Adenocarcinoma with an Endoscope: The Ultimate in Minimally Invasive, Curative Therapy
Curr Surg Rep (2014) 2:66 DOI 10.1007/s40137-014-0066-x ESOPHAGEAL/REFLUX SURGERY (SR DEMEESTER, SECTION EDITOR) Treatment of High-Grade Dysplasia and Early Stage Esophageal Adenocarcinoma with an Endoscope:
More informationHenry Moon was one of the giants in academic pathology during my early years.
Henry Moon was one of the giants in academic pathology during my early years. Controversial stuff that occurs slightly above, within or slightly below the gastroesophageal junction, including Barrett s
More informationThe increasing incidence of esophageal adenocarcinoma
GASTROENTEROLOGY 2004;127:310 330 A Critical Review of the Diagnosis and Management of Barrett s Esophagus: The AGA Chicago Workshop PRATEEK SHARMA,* KENNETH MCQUAID, JOHN DENT, M. BRIAN FENNERTY, RICHARD
More informationBarrett Esophagus - RadioFrequency Ablation (BE-RFA) - Project manual + FAQ
Barrett Esophagus - RadioFrequency Ablation (BE-RFA) - Project manual + FAQ Table of contents 1 General project information...3 1.1 Inclusion criteria...3 1.2 Registration time points...3 1.3 Project variable
More informationTreat Barrett s, Remove the Risk. HALO System
Treat Barrett s, Remove the Risk HALO System The HALO 360 System Advanced Ablation Technology for Barrett s Esophagus The HALO 360 System is designed to remove the Barrett s epithelium in a short, well-tolerated
More informationBarrett s esophagus, reflux esophagitis, and eosinophilic esophagitis F. P. Vleggaar, P. D. Siersema Utrecht, the Netherlands
DDW HIGHLIGHTS F. P. Vleggaar, P. D. Siersema Utrecht, the Netherlands Many new and exciting endoscopy-related studies on Barrett s esophagus, reflux esophagitis, and eosinophilic esophagitis were presented
More informationColon Polyps: Detection, Inspection and Characteristics
Colon Polyps: Detection, Inspection and Characteristics Stephen Kim, M.D. Assistant Professor of Medicine Interventional Endoscopy Services UCLA Division of Digestive Diseases September 29, 2018 1 Disclosures
More informationBarrett s esophagus: lessons from recent clinical trials
INVITED REVIEW Annals of Gastroenterology (2016) 29, 1-7 Barrett s esophagus: lessons from recent clinical trials Daniela Golger, Andreas Probst, Helmut Messmann Klinikum Augsburg, Germany Abstract Data
More informationESOPHAGEAL CANCER. Epidemiology 3/22/2017. Esophageal Carcinoma: subtypes. Esophageal Adenocarcinoma (EAC) Epidemiology.
ESOPHAGEAL CANCER Disclosures Sushil Ahlawat, MD, FACP, FASGE, AGAF Associate Professor of Medicine Director of Endoscopy RUTGERS NJMS Nothing to disclose. Esophageal Carcinoma: subtypes Subtype Squamous
More informationRADIOFREQUENCY ABLATION OR CRYOABLATION FOR ESOPHAGEAL DISORDERS
DISORDERS Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are dependent
More informationDysplasia 4/19/2017. How do I practice Chromoendoscopy for Surveillance of Colitis? SCENIC: Polypoid Dysplasia in UC. Background
SCENIC: Polypoid in UC Definition How do I practice for Surveillance of Colitis? Themos Dassopoulos, M.D. Director, BSW Center for IBD Themistocles.Dassopoulos@BSWHealth.org Tel: 469-800-7189 Cell: 314-686-2623
More informationChapter 12: Training in Pathology. DDSEP Chapter 13: Question 19
DDSEP Chapter 13: Question 19 A 70 year-old male with a history of celiac disease diagnosed in his forties reports abdominal pain, dark stools, and 20-pound weight loss. He reports complete compliance
More informationChromoendoscopy - Should It Be Standard of Care in IBD?
Chromoendoscopy - Should It Be Standard of Care in IBD? John F. Valentine, MD, FACG Professor of Medicine Division of Gastroenterology, Hepatology and Nutrition University of Utah What is the point of
More informationAccepted Manuscript. En bloc resection for mm polyps to reduce post-colonoscopy cancer and surveillance. C. Hassan, M. Rutter, A.
Accepted Manuscript En bloc resection for 10-20 mm polyps to reduce post-colonoscopy cancer and surveillance C. Hassan, M. Rutter, A. Repici PII: S1542-3565(19)30412-4 DOI: https://doi.org/10.1016/j.cgh.2019.04.022
More informationBarrett's Esophagus and Indications for Anti-reflux Procedures. Gamal Marey SUNY Downstate Medical Center (RUMC) 7/3/2014
Barrett's Esophagus and Indications for Anti-reflux Procedures Gamal Marey SUNY Downstate Medical Center (RUMC) 7/3/2014 History 46 y/o. female, 109 lbs, with PMH significant for long standing acid reflux
More informationTools of the Gastroenterologist: Introduction to GI Endoscopy
Tools of the Gastroenterologist: Introduction to GI Endoscopy Objectives Endoscopy Upper endoscopy Colonoscopy Endoscopic retrograde cholangiopancreatography (ERCP) Endoscopic ultrasound (EUS) Endoscopic
More informationAre You Living with Barrett s Esophagus?
Are You Living with Barrett s Esophagus? Wouldn t you rather live without it? If you re living with Barrett s esophagus you are not alone. Barrett s esophagus is caused by the long-term exposure of your
More informationGenomic Diversity in Barrett s esophagus predicts long term progression.., Soesterberg, Prof. dr. Sheila Krishnadath
Genomic Diversity in Barrett s esophagus predicts long term progression.., Soesterberg, Prof. dr. Sheila Krishnadath 14-03-2018 Esophageal squamous cell carcinoma Risk factors - Alcohol - Smoking - Male
More informationConfocal Laser Endomicroscopy
Confocal Laser Endomicroscopy Policy Number: 2.01.87 Last Review: 3/2018 Origination: 3/2013 Next Review: 9/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will not provide coverage for
More informationCarol A. Burke, MD, FACG
Updated Guidelines for CRC C Screening and Surveillance Carol A. Burke MD, FACG, FASGE, FACP Cleveland Clinic, Cleveland, OH Gastroenterology t 2012;143:844 143 Gut 2010;59:666 1 Caveat for all Recommendations
More information